Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 1;79(7):736-738.
doi: 10.1001/jamapsychiatry.2022.1074.

Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting

Sina Nikayin  1 , Taeho Greg Rhee  1 , Maria Elena Cunningham  2 , Christina A de Fontnouvelle  3 , Robert B Ostroff  1 , Gerard Sanacora  1 , Samuel T Wilkinson  1
Affiliations
Comment

Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting

Sina Nikayin et al. JAMA Psychiatry. .

Abstract

This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Sanacora reported receiving personal fees and serving as a consultant to Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Cowen, EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported.

Figures

Figure.
Figure.. Estimated Differences of Groups Treated With Intravenous Ketamine or Intranasal Esketamine
Patients received intravenous (IV) ketamine (0.5 mg/kg over 40 minutes) or intranasal (IN) esketamine (56 or 84 mg) to treat depression. Their depression trajectories were assessed using scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR).
See this image and copyright information in PMC

Comment on

References

    1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. doi: 10.1016/S0006-3223(99)00230-9 - DOI - PubMed
    1. Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527-534. doi: 10.1016/j.jad.2019.11.086 - DOI - PubMed
    1. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542-555. doi: 10.1016/j.jad.2020.09.071 - DOI - PMC - PubMed
    1. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080. doi: 10.1136/bmj.332.7549.1080 - DOI - PMC - PubMed
    1. Sakurai H, Jain F, Foster S, et al. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: a retrospective chart review. J Affect Disord. 2020;276:660-666. doi: 10.1016/j.jad.2020.07.089 - DOI - PubMed

MeSH terms